BPMC240517C105000
- 1.50
- 0.000.00%
Blueprint Medicines Newsroom
Blueprint Medicines (NASDAQ:BPMC) Pulls Back 3.5% This Week, but Still Delivers Shareholders Notable 85% Return Over 1 Year
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Blueprint Medicines Corporation's (NASDAQ:BPMC) price-to-sales (or "P/S") ratio of 23.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where a
Blueprint Medicines(BPMC.US) Officer Sells US$626.38K in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Hurley Ariel sold 5,856 shares of common stock on May 15, 2024 at an average price of $106.96 for a total value of $626.38K.Source: Announcement What is statemen
Blueprint Medicines(BPMC.US) Officer Sells US$411.77K in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Landsittel Michael sold 3,850 shares of common stock on May 15, 2024 at an average price of $106.95 for a total value of $411.77K.Source: Announcement What is st
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 411.78K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Blueprint Medicines(BPMC.US)$ Officer MICHAEL LANDSITTEL intends to sell 3,850 shares of its common stock on May 15, with a total market value of approximately $411.78
Form 144 | Blueprint Medicines(BPMC.US) Officer Proposes to Sell 626.36K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Blueprint Medicines(BPMC.US)$ Officer ARIEL HURLEY intends to sell 5,856 shares of its common stock on May 15, with a total market value of approximately $626.36K. A
Blueprint Medicines Started at Buy by Stephens, Citing Ayvakit Franchise
Unveiling 18 Analyst Insights On Blueprint Medicines
Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent
Express News | Blueprint Medicines Corp : Stephens Initiates Coverage With Overweight Rating; Price Target $140
Blueprint Medicines Initiated at Overweight by Stephens & Co.
Blueprint Medicines Initiated at Overweight by Stephens & Co.
Blueprint Medicines Price Target Announced at $140.00/Share by Stephens & Co.
Blueprint Medicines Price Target Announced at $140.00/Share by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On Blueprint Medicines With Overweight Rating, Announces Price Target of $140
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Blueprint Medicines(BPMC.US) Officer Sells US$1.05 Million in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Landsittel Michael sold 10,000 shares of common stock on May 2, 2024 at an average price of $105 for a total value of $1.05 million.Source: Announcement What is
Blueprint Medicines(BPMC.US) Officer Sells US$190.52K in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Hurley Ariel sold 1,834 shares of common stock on May 2, 2024 at an average price of $103.88 for a total value of $190.52K.Source: Announcement What is statement
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing
Michael Landsittel, CFO, on May 02, 2024, sold 10,000 shares in Blueprint Medicines (BPMC) for $1,050,000. Following the Form 4 filing with the SEC, Landsittel has control over a total of 47,286 share
Express News | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Blueprint Medicines Raised to Market Perform From Underperform by Leerink Partners
Blueprint Medicines Raised to Market Perform From Underperform by Leerink Partners
Express News | Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97